A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs ADVAX (Primary) ; PanBlok (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- Sponsors Vaxine
- 06 May 2019 Status changed from active, no longer recruiting to completed.
- 20 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2018.
- 20 Nov 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.